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OBJECTIVES: To examine the frequency and nature of
FDA regulatory actions against pharmaceutical compa-
nies for unsubstantiated or misleading economic and
quality-of-life (QOL) claims. 
METHODS: Review of publicly-available FDA warning
letters and notices of violation (n = 566) sent to pharma-
ceutical companies between January 1997 and November
2001 for inappropriate promotional claims. A standard
data collection form was developed to capture the 
frequency and type of violation and the medium in which
violations were found. We classiﬁed economic violations
into several categories (e.g., “unsupported comparative
claim of effectiveness, safety or interchangeability,”
“claims of cost-savings when there are obvious additional
costs that may affect cost savings,” “implied claims of
cost-savings to a broader audience than applicable”).
QOL violations for false or misleading claims using the
words improved ‘quality of life’ or ‘patient well-being’
were classiﬁed into the following categories: “lack of 
substantial evidence for QOL claims,” “promoting 
QOL claims in investigational or unapproved drug,” and
“selective presentation of QOL information”.
RESULTS: 28 (4.9%) letters cited false and/or mislead-
ing economic claims. The most common economic viola-
tion was an economic claim containing an “unsupported
comparative claim of effectiveness, safety or interchange-
ability” (n = 14). 28 (4.9%) letters cited QOL violations
(4 letters contained both economic and QOL violations).
The most common QOL violation was “lack of substan-
tial evidence for QOL claims” (n = 15). Violations were
found most frequently in brochures and on websites.
CONCLUSIONS: A body of evidence is emerging that
illustrates how the FDA is regulating promotional mate-
rial containing misleading or unsubstantiated economic
and QOL claims. Knowing what constitutes an economic
or QOL violation remains unclear, because there are no
formal guidelines about what constitutes a violation, nor
what level of substantiating evidence is required. More
guidance may be needed to ensure appropriate use in drug
promotions.
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OBJECTIVE: In health services research, obtaining 
objective measures of pulmonary function to classify
asthma severity is often not possible. Researchers must
rely on methods such as frequency of self-reported symp-
toms and patient perceived severity. This study examined
the relationship between FEV1 determined severity and
severity determined by patient-reported information. 
METHODS: Data from adult patients with asthma were
obtained from a pulmonary clinic via chart review and
patient self-report during a scheduled physician visit.
Patients in acute exacerbation were excluded. Patient-
Perceived Severity (PPS) was determined by asking 
“How severe do you think your asthma is?” with a 
ﬁve-point Likert scale from Very Mild to Very Severe.
Overall Symptom-derived Severity (OSS) and Nocturnal
Symptom-derived Severity (NSS) were determined from
two separate questions regarding symptom frequency
during the preceding four weeks. Responses were based
on the NHLBI 1997 Asthma Guidelines. Pulmonary func-
tion tests were obtained the same day as part of standard
care. FEV1-Determined Severity (FEV1-DS) was derived
by comparing the FEV1 with the Guideline classiﬁcation
of severity based on spirometry. Three severity categories
were derived for each severity method. Percent agreement
between FEV1-DS and each patient-reported severity 
was determined by constructing 3 ¥ 3 tables. Correlations
(Spearman’s rho) were conducted between FEV1-DS and
the patient-reported severity measures.
RESULTS: 57 patients with a mean FEV1 percent 
predicted of 80.2% (27.5) were studied. The percent
agreement between FEV1-DS and PPS was 59.7%
(33.3% over-estimate, 7.0% under-estimate); 56.4%
between FEV1-DS and OSS (14.5% over-estimate, 
29.1% under-estimate); and 40.7% between FEV1-DS
and NSS (25.9% over-estimate, 33.3% under-estimate).
The correlations between FEV1-DS and PPS were 0.58 (p
< 0.01); 0.53 with OSS (p < 0.01); and 0.13 with NSS (p
= 0.13).
CONCLUSIONS: PPS and OSS demonstrated reasonable
agreement and correlation to FEV1-DS, albeit opposite
trends in over- and under-estimates. These two measures
of asthma severity appear useful for population based
studies when FEV1 is unavailable.
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OBJECTIVES: Several empiric algorithms have been
developed to derive preference estimates from the SF-36.
The objective of this study was to compare the validity
and responsiveness of SF-36 derived preference estimates
to directly elicited preferences in persons with persistent
asthma. 
METHODS: We used data from a one-year clinical trial
of adult asthmatics to derive preferences from the SF-36.
Preferences were estimated using ﬁve published algo-
rithms for converting SF-36 scores to non-choice based
preference estimates. Derived preferences were compared
to directly elicited visual analog scale (VAS) values.
